PRICE, HENEVELD, COOPER, DEWITT & LITTON, LLP

ATTORNEYS AT LAW

PATENT, TRADEMARK & COPYRIGHT CAUSES

695 KENMOOR S.E. P.O. BOX 2567

GRAND RAPIDS. MICHIGAN 49501 TELEPHONE (616) 949-9610

> FAX (616) 957-8196 www.priceheneveld.com

MARCUS P. DOLCE AARON J. WONG BRIAN R. CHESLEK JASON L. BUDD SCOTT P. RYAN PAUL A. RODRIGUEZ

PETER P. PRICE (1918-2000) LLOYD A. HENEVELD (1925-2000) THOMAS M. McKINLEY (1947-1994)

OF COUNSEL
RICHARD C. COOPER
WILLIAM W. DEWITT
RANDALL G. LITTON
FRANK M. SCUTCH III
LISA R. HARRIS

HAROLD W. REICK

DANIEL L. GIRDWOOD

TERRY S. CALLAGHAN

GUNTHER J. EVANINA

TODD A. VAN THOMME.

BRIAN E. AINSWORTH

MATTHEW J. GIPSON

JEFFREY S. KAPTEYN

STEVEN L. UNDERWOOD

DOUGLAS H. SIEGEL

KEVIN T. GRZELAK

CARL S. CLARK

FACSIMILE TRANSMITTAL SHEET				
то: Examiner Wollenberger		_{FROM:} Douglas H. Siegel		
COMPANY: USPTO		9/30/2009		
FAX NUMBER: 571-273-8144		TOTAL NO. OF PAGES INCLUDING COVER:		
PHONE NUMBER: 571-272-8144		sender's reference number: VAN67 P328A		
US Serial No. 10/599,327		YOUR REFERENCE NUMBER:		
URGENT	☑ FOR REVIEW	☐ PLEASE COMMENT	☐ PLEASE REPLY	☐ PLEASE RECYCLE
NOTES/COMMENTS:		. .		

Examiner Wollenberger:

Further to our interview of September 16, 2009, and in anticipation of our interview scheduled for October 6, 2009, at 10:30, I have attached a copy of the proposed claims for your review. Thank you.

THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE PERSONAL USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE. This facsimile transmission may also be an attorney/client communication, which is privileged and confidential. If the reader of this message is not the intended recipient, the employee, or agent responsible to deliver it to the intended recipient, you are hereby notified that any distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately call us collect by telephone and return the original message to us at the above address via the United States Postal Service. Thank you.

Please call 616/949-9610, and ask for Anna Weiss, if there is any problem with reception of this transmission.

PRICE HENEVELD 1 04:52:25 p.m. 09-30-2009 2/6

1

Applicant

: Nariyoshi Shinomiya et al.

Appln. No. : 10/599,327

Page

: 1

DRAFT PROPOSED AMENDED CLAIMS - okay to scan [do not enter]

1. (Canceled)

2. (Currently amended) The RNAi molecule of claim 41 that is a single stranded

siRNA that forms a hairpin structure.

3. (Currently amended) The RNAi molecule of claim 44 that is a double stranded

siRNA.

4. (Currently amended) An interfering RNA (RNAi) molecule that comprises The

RNAi molecule-of-claim 1 that (i) comprises, or (ii) hybridizes to a Met target sequence

that comprises, a sequence selected from the group consisting of: (a) SEQ ID NO:9; (b)

SEQ ID NO:10; (c) SEQ ID NO:11; (d) SEQ ID NO:12; (e) SEQ ID NO:13; (f) SEQ ID

NO:14; (g) SEQ ID NO:15; (h) SEQ ID NO:16; (i) SEQ ID NO:17; and (j) SEQ ID

NO:18.

5-7. (Canceled)

8. (Currently amended) A DNA molecule encoding the RNAi molecule of claim 41. PRICE HENEVELD 1 04:52:34 p.m. 09–30–2009

3/6

Applicant

: Nariyoshi Shinomiya et al.

Appln. No.

: 10/599,327

Page

: 2

9. (Currently Amended) An expression construct comprising DNA that encodes the

RNAi molecule of claim 41 operatively linked to a promoter that drives the expression of

said RNAi molecule in a c-met-expressing cell.

10. (Original) An expression construct comprising the DNA molecule of claim 8.

11. (Currently Amended) The expression construct of claim 9, wherein a promoter is

one that drives the expression of said RNAi molecule in a c-met-expressing tumor or

cancer cell.

12. (Previously presented) The expression construct of claim 11 wherein the promoter

is a polIII promoter.

13. (Original) The expression construct of claim 12 wherein the polIII promoter is a

U6 promoter.

14. (Previously presented) A viral vector comprising the expression construct of

claim 9.

15. (Original) The viral vector of claim 14 that is a transient expression vector.

PRICE HENEVELD 1 04:52:42 p.m. 09–30–2009 4/6

Applicant : Nariyoshi Shinomiya et al.

Appln. No. : 10/599,327

Page: 3

16. (*Currently amended*) The viral vector of claim <u>14</u> <u>13</u> that is a stable expression vector.

- 17. (Previously presented) The viral vector of claim 14 that is an adenoviral vector.
- 18. (Original) The adenoviral vector of claim 17 that is an Ad5 viral vector.
- 19. (*Original*) The Ad5 viral vector of claim 18 selected from the group consisting of: (a) si-mMet-Ad5⁵⁷; (b) si-mMet-Ad5⁶⁰; (c) si-mMet-Ad5¹¹⁰; (d) si-mMet-Ad5¹⁷⁸; (e) si-hMet-Ad5¹⁶; (f) si-hMet-Ad5⁶²; (g) si-hMet-Ad5²²¹; (h) si-dMet-Ad5¹¹¹; (i) si-dMet-Ad5¹⁹⁷; and (j) si-dMet-Ad5²²³.
- 20. (*Original*) The Ad5 viral vector of claim 19 wherein the vector is si-hMet-Ad5¹⁶, si-hMet-Ad5⁶²; or si-hMet-Ad5²²¹.

21-37. (Canceled)

38. (*Previously presented*) A method of treating a c-met⁺ tumor or cancer in a subject, comprising administering to the subject by an effective route, an amount of the viral vector of claim 14 effective for inhibiting expression of c-met and thereby (i) inhibiting the growth, invasion or metastasis of cells of said tumor or cancer, or (ii) killing said

PRICE HENEVELD 1 04:52:52 p.m. 09–30–2009 5/6

Applicant

: Nariyoshi Shinomiya et al.

Appln. No.

: 10/599,327

Page

: 4

tumor or cancer cells.

39-47. (Canceled)

- 48. (*Previously presented*) The method of claim 38 wherein the tumor or cancer is glioblastoma, prostate or gastric.
- 49. (*Previously presented*) A method of treating a c-met⁺ tumor or cancer in a subject, comprising administering to the subject by an effective route, an amount of the viral vector of claim 19 effective for inhibiting expression of c-met and thereby (i) inhibiting the growth, invasion or metastasis of cells of said tumor or cancer, or (ii) killing said tumor or cancer cells.
- 50. (*Previously presented*) The method of claim 49 wherein the tumor or cancer is glioblastoma, prostate or gastric.
- 51. (New) A method of treating a human subject in need of treatment for a c-met[†] tumor or cancer comprising administering to the subject a viral vector comprising DNA that encodes an interfering RNA (RNAi) molecule, which DNA is operatively linked to a promoter that drives the expression of the RNAi molecule in a c-met-expressing cell, wherein the RNAi molecule has a sequence that is sufficiently complementary to a

PRICE HENEVELD 1 04:53:02 p.m. 09–30–2009 6 /6

Applicant : Nariyoshi Shinomiya et al.

Appln. No. : 10/599,327

Page: 5

sequence of mRNA encoded by human c-met (SEQ ID NO:1) so that expression of the RNAi molecule in a cell that normally expresses c-met results in diminution or loss of expression of the mRNA.